Agios Pharmaceuticals, Inc. (AGIO) Financial Statements (2023 and earlier)

Company Profile

Business Address 88 SIDNEY STREET
CAMBRIDGE, MA 02139
State of Incorp. DE
Fiscal Year End December 31
Industry (SIC) 2834 - Pharmaceutical Preparations (benchmarking)
More info Complete Financial Analysis Financial Benchmarking

Balance Sheet (Statement of Financial Position) ($ in thousands)

3/31/2023
MRQ
12/31/2022
12/31/2021
12/31/2020
12/31/2019
12/31/2018
12/31/2017
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments, including:1,100,0001,286,400670,500717,800805,400567,800
Cash and cash equivalents139,259203,126127,43680,93170,502102,724
Short-term investments643,860816,892445,493483,946514,800321,212
Other undisclosed cash, cash equivalents, and short-term investments316,881266,38297,571152,923220,098143,864
Receivables(60) (902)(540)(326) 
Inventory, net of allowances, customer advances and progress billings8,492 14,6987,331869 
Inventory8,492 14,6987,331869 
Contract with customer, asset, after allowance for credit loss2,206 21,3288,952 
Other undisclosed current assets(277,866)(222,169)(68,947)(121,839)(192,163)(122,539)
Total current assets:832,7721,064,231636,677611,704613,780445,261
Noncurrent Assets
Finance lease, right-of-use asset, after accumulated amortization  183590993
Operating lease, right-of-use asset65,12975,12484,66193,643
Property, plant and equipment22,98728,92332,29131,47224,32024,431
Long-term investments and receivables313,874266,37597,608152,929220,119143,814
Long-term investments313,874266,37597,608152,929220,119143,814
Other noncurrent assets3,9562,9001,125 238891
Total noncurrent assets:405,946373,505216,275279,037244,677169,136
TOTAL ASSETS:1,238,7181,437,736852,952890,741858,457614,397
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities48,96648,66786,98475,03860,02756,798
Accounts payable18,61616,70026,84421,89617,88022,767
Accrued liabilities30,35031,96760,14053,14242,14734,031
Deferred revenue    10,933
Debt  3313176,915  
Deferred revenue and credits76638,143
Other undisclosed current liabilities13,66310,8287,093 32,710 
Total current liabilities:62,62959,82694,39492,88693,50394,941
Noncurrent Liabilities
Long-term debt and lease obligation  85,93597,789106,747  
Finance lease, liability  276331673
Liabilities, other than long-term debt75,275  50,58017,608143,953
Deferred revenue and credits17,608143,953
Deferred revenue    50,580
Other liabilities3,279     
Operating lease, liability71,99685,65997,458106,074
Other undisclosed noncurrent liabilities  (85,659)163,811 59,809 
Total noncurrent liabilities:75,27585,935359,058157,32777,417143,953
Total liabilities:137,904145,761453,452250,213170,920238,894
Equity
Equity, attributable to parent, including:1,100,8141,291,975399,500640,528687,537375,503
Common stock  7169685849
Treasury stock, value(802,486)(802,486)    
Additional paid in capital2,386,3252,334,3482,242,8012,156,3631,794,2831,174,904
Accumulated other comprehensive income (loss)(12,535)(1,198)105202(2,171)(1,389)
Accumulated deficit(470,561)(238,760)(1,843,475)(1,516,105)(1,104,633)(798,061)
Other undisclosed equity, attributable to parent71     
Total equity:1,100,8141,291,975399,500640,528687,537375,503
TOTAL LIABILITIES AND EQUITY:1,238,7181,437,736852,952890,741858,457614,397

Income Statement (P&L) ($ in thousands)

3/31/2023
TTM
12/31/2022
12/31/2021
12/31/2020
12/31/2019
12/31/2018
12/31/2017
Revenues14,240500203,196117,91294,38743,011
Revenue, net43,011
Sublease income 500  
Cost of revenue(1,704) (2,805)(1,317)(1,397) 
Cost of goods and services sold(1,704) (2,805)(1,317)(1,397) 
Gross profit:12,536500200,391116,59592,99043,011
Operating expenses(401,583)(378,418)(516,540)(542,928)(456,866)(363,805)
Other undisclosed operating income (loss)  (500)  1,397 
Operating loss:(389,047)(378,418)(316,149)(426,333)(362,479)(320,794)
Nonoperating income29,39315,2696,61114,86116,4516,124
Investment income, nonoperating22,6448366,61114,86116,4516,124
Other nonoperating income6,74914,433    
Other undisclosed loss from continuing operations before equity method investments, income taxes   (17,911)   
Loss from continuing operations before equity method investments, income taxes:(359,654)(363,149)(327,449)(411,472)(346,028)(314,670)
Other undisclosed income from continuing operations before income taxes127,8536,639    
Loss from continuing operations:(231,801)(356,510)(327,449)(411,472)(346,028)(314,670)
Loss before gain (loss) on sale of properties:(356,510)(327,449)(411,472)(346,028)(314,670)
Net loss:(231,801)(356,510)(327,449)(411,472)(346,028)(314,670)
Other undisclosed net income (loss) attributable to parent 1,961,22579   
Net income (loss) available to common stockholders, diluted:(231,801)1,604,715(327,370)(411,472)(346,028)(314,670)

Comprehensive Income ($ in thousands)

3/31/2023
TTM
12/31/2022
12/31/2021
12/31/2020
12/31/2019
12/31/2018
12/31/2017
Net loss:(231,801)(356,510)(327,449)(411,472)(346,028)(314,670)
Other comprehensive loss      
Comprehensive loss:(231,801)(356,510)(327,449)(411,472)(346,028)(314,670)
Other undisclosed comprehensive income (loss), net of tax, attributable to parent(11,337)1,959,922(18)2,373(782)(1,076)
Comprehensive income (loss), net of tax, attributable to parent:(243,138)1,603,412(327,467)(409,099)(346,810)(315,746)

Statements Sources

The financial statements are based on the Company's filings with the U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: